Pay in 4 interest-free payments of $9.75 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Phase I clinical trial studies showed that in humans
Selectively toxic towards tumor cells
Ropelle ER
Specificity studies have shown that it has no activity on GLP-2
is a potent and selective histone deacetylase HDAC4 and HDAC5 inhibitor (IC50 ~11
BG45 - HDAC3 Inhibitor. CAS# 926259-99-6 Catalog No.:M60266-10S Phase I clinical trial studiesBG45, CAS No. 926259 99 6, is a potent, selective and cell permeable HDAC3 inhibitor. It inhibits HDAC3 with IC50 of 289 nM. It has IC50 of 2. 0 M, 2. 2 M and >20 M for HDAC1, HDAC2, and HDAC6 in cell free assays, respectively. BG45 triggers significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP ribose) polymerase cleavage. BG45 alone and in combination with bortezomib triggers significant tumor growth inhibition in
US$ 1299.00
US$ 1381.50
US$ 802.00
US$ 877.00
US$ 480.00
US$ 425.00